metadex xr 40 mg
k.s.kim international (sk- pharma) ltd., israel - dexmethylphenidate hydrochloride - capsules extended release - dexmethylphenidate hydrochloride 40 mg - dexmethylphenidate - metadex xr extended-release capsules are a central nervous system (cns) stimulant indicated for the treatment of attention deficit hyperactivity disorder (adhd) in children of 6 years and older, in adolescents and in adults.
metadex xr 5 mg
k.s.kim international (sk- pharma) ltd., israel - dexmethylphenidate hydrochloride - capsules extended release - dexmethylphenidate hydrochloride 5 mg - dexmethylphenidate - metadex xr extended-release capsules are a central nervous system (cns) stimulant indicated for the treatment of attention deficit hyperactivity disorder (adhd) in children of 6 years and older, in adolescents and in adults.
fampridine s.k. 10 mg
k.s.kim international (sk- pharma) ltd., israel - fampridine - tablets prolonged release - fampridine 10 mg - fampridine - fampridine s.k. is indicated for the improvement of walking in adult patients with multiple sclerosis with walking disability (edss 4-7).
difumar s.k. 120 mg
k.s.kim international (sk- pharma) ltd., israel - dimethyl fumarate - capsules delayed release - dimethyl fumarate 120 mg - dimethyl fumarate - difumar s.k. is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis
difumar s.k. 240 mg
k.s.kim international (sk- pharma) ltd., israel - dimethyl fumarate - capsules delayed release - dimethyl fumarate 240 mg - dimethyl fumarate - difumar s.k. is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis
palonosetron s.k.
k.s.kim international (sk- pharma) ltd., israel - palonosetron as hydrochloride - solution for injection - palonosetron as hydrochloride 250 mcg / 5 ml - palonosetron - palonosetron s.k. is indicated in adults and in paediatric patients 1 month of age and older for the prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy, and prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy.
bendamustine s.k. 100 mg
k.s.kim international (sk- pharma) ltd., israel - bendamustine as hydrochloride monohydrate - powder for concentrate for solution for infusion - bendamustine as hydrochloride monohydrate 100 mg/vial - bendamustine - first-line of chronic lymphocytic leukaemia (binet stage b or c) in patients for whom fludarabine combination chemotheraphy is not appropiate. indolent non-hodgkin’s lymphomas as monotheraphy in patients, who have progressed during or within 6 months following treatment with rituximab or a rituximab containing regimen. follicular non-hodgkin’s lymphoma as first line treatment in combination with rituximab.
bendamustine s.k. 25 mg
k.s.kim international (sk- pharma) ltd., israel - bendamustine as hydrochloride monohydrate - powder for concentrate for solution for infusion - bendamustine as hydrochloride monohydrate 25 mg/vial - bendamustine - first-line of chronic lymphocytic leukaemia (binet stage b or c) in patients for whom fludarabine combination chemotheraphy is not appropiate. indolent non-hodgkin’s lymphomas as monotheraphy in patients, who have progressed during or within 6 months following treatment with rituximab or a rituximab containing regimen. follicular non-hodgkin’s lymphoma as first line treatment in combination with rituximab.
vinorelbine s.k. 20 mg
k.s.kim international (sk- pharma) ltd., israel - vinorelbine as tartrate - capsules soft - vinorelbine as tartrate 20 mg - vinorelbine - vinorelbine s.k. is indicated :- for the treatment of non small cell lung cancer. - for the treatment of advanced breast cancer
vinorelbine s.k. 30 mg
k.s.kim international (sk- pharma) ltd., israel - vinorelbine as tartrate - capsules soft - vinorelbine as tartrate 30 mg - vinorelbine - vinorelbine s.k. is indicated : - for the treatment of non small cell lung cancer - for the treatment of advanced breast cancer